Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Nutriband Inc. (NTRB) stock declined over -2.38% intraday to trade at $4.11 a share on NASDAQ. The stock opened with a loss of -1.91% at $4.07 and touched an intraday high of $4.16, falling -2.38% against the last close of $4.21. The stock went to a low of $3.76 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $4.07 | $4.16 | $3.76 | $4.11 | 11,657 |
2022-06-29 | $4.19 | $4.36 | $4.03 | $4.21 | 4,400 |
2022-06-28 | $4.79 | $4.845 | $4.3 | $4.35 | 19,500 |
2022-06-27 | $4.01 | $5.08 | $3.96 | $4.98 | 85,300 |
2022-06-24 | $3.064 | $3.92 | $3.06 | $3.92 | 18,700 |
2022-06-23 | $3.09 | $3.34 | $3.07 | $3.25 | 24,100 |
2022-06-22 | $3 | $3.19 | $2.81 | $2.81 | 12,100 |
2022-06-21 | $3.28 | $3.28 | $2.86 | $2.86 | 11,600 |
2022-06-17 | $3.2 | $3.4 | $2.96 | $2.96 | 10,600 |
2022-06-16 | $3.22 | $3.66 | $3.2 | $3.2 | 10,100 |
Employees-
Beta-0.28
Sales or Revenue1.42 Million
5Y Sales Change-
Fiscal Year Ends2022-01-30
SectorHealth Care
IndustryPharmaceuticals
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc. (NASDAQ: NTRB) stock price is $4.11 as of the last check on Thursday, June 30. During the trading session, NTRB stock reached the peak price of $4.16 while $3.76 was the lowest point it dropped to.
The NASDAQ listed NTRB is part of Pharmaceuticals industry that operates in the broader Health Care sector. Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
Mr. Serguei Melnik
Founder, Pres, Company Sec. & Exec. Chairman
Mr. Gareth Sheridan
Founder, CEO & Director
Dr. Jeffrey Patrick
Chief Scientific Officer
Mr. Gerald Goodman
CFO & Chief Accounting Officer
NTRB stock traded closed the last session at $4.11, which is $-0.10 or -2.38% lower than its previous close of $4.21. NTRB's current trading price is 46.26% lower than its 52-week high of $15.00 where as its distance from 52-week low of 2.81% is -72.60%.
Number of NTRB employees currently stands at -. NTRB operates from 121 South Orange Avenue, Suite 1500, Orlando, FL 32801, United States.
Official Webiste of $NTRB is: https://nutriband.com
NTRB could be contacted at NTRB operates from 121 South Orange Avenue, Suite 1500, Orlando, FL 32801, United States, or at phone #407 377 6695 and can also be accessed through its website.
NTRB stock volume for the day was 11,657 shares while in the previous session number of NTRB shares traded was 11,657 . The average number of NTRB shares traded daily for last 3 months was 14.85 Thousands.
The percentage change in NTRB stock occurred in the recent session was -2.38% while the dollar amount for the price change in NTRB stock was $-0.10.
In the recent session, the day high for NTRB stock was $4.16 while the low for NTRB stock touched on the day was $3.76.
The market value of NTRB currently stands at 26.76 Million with its latest stock price at $4.11 and 7.87 Million of its shares outstanding.